Evidence status: CURRENT BINDING STATE REQUIREMENT. Rhode Island’s active pain-management regulation requires a written patient treatment agreement for chronic-pain patients receiving opioid medication, no later than after 90 days of treatment. Rhode Island’s 2026 controlled-substances legislation also expressly incorporates written patient treatment agreements under Department of Health regulations.

Quick read

Under 216-RICR-20-20-4.4(F), a chronic-pain patient receiving opioid medication must have a written patient treatment agreement that becomes part of the medical record. The agreement may begin sooner based on patient history and risk, but it must be in place no later than after 90 days of opioid treatment. At minimum, the practitioner and patient or patient proxy sign it.

The 2026 statutory layer

Public Law 2026, Chapter 314, enacted June 23, 2026, revised Rhode Island’s Uniform Controlled Substances Act. It added a definition of chronic pain as pain lasting at least 90 days, excluding chronic intractable pain, and amended §21-28-3.20.1. For the conditions covered by that section, the statute says practitioners must enter into a written patient treatment agreement in accordance with Department of Health regulations.

What the regulation says the agreement may include

  • Taking medication at the prescribed dose and frequency, including a protocol for lost prescriptions and early refills.
  • Reasons medication therapy may be discontinued, including agreement violations or lack of effectiveness.
  • Use of a single practitioner or limited agreed group for chronic-pain prescriptions.
  • An agreement not to abuse alcohol or use medically unauthorized substances or medications.
  • Acknowledgment that a violation may lead to a treatment-plan change or referral to substance-use-disorder treatment.
  • Random toxicology screening at the practitioner’s discretion.

Important classification point: the regulation introduces these items with discretionary language. The binding requirement is the existence, timing, record placement, and minimum signatures of the written agreement. A particular clinic’s chosen clauses must still be distinguished from universal state mandates.

Related statewide requirements outside the agreement

  • The PDMP must be reviewed before initially prescribing an opioid and at least every three months for patients under active ongoing opioid treatment.
  • Periodic review, including an in-person visit, must occur at intervals not exceeding six months.
  • The practitioner must document a treatment plan and evaluate adherence, function, pain, quality of life, and whether continuation or modification is necessary.

Long-acting and extended-release opioids

The same regulation separately requires a written treatment agreement for patients receiving long-acting or extended-release opioid medication on a long-term basis of 90 days or more. The agreement must be in the record and signed at minimum by the practitioner and patient or proxy.

What this page does not claim

This page does not treat every term in the RIDOH sample agreement, provider manual, or an individual clinic contract as a separate state mandate. Nor does it determine whether a clause is enforceable in an individual dispute. It records the current public legal baseline.

Primary sources

← Rhode Island Contract-for-Care Evidence Library

Reviewed: October 4, 2026.

Evidence boundary: Applicability depends on the treatment circumstances and the scope of the cited law and regulation. This is a public-source record, not patient-specific legal advice.